Tag: Aimmune Therapeutics
Study Determines What Patients Prefer for Maintenance After Completing OIT with...
Patients chose from continuing with Palforzia or switching to a common food.
Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...
73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.
You’re Invited: Patient and Advocacy Educational Presentation by Aimmune Therapeutics
Two events in NJ: Parsippany and Eatontown.
Nestlé Acquires Aimmune, Partners with Enterome to Develop Food Allergy and...
Nestlé, the consumer products powerhouse, is expanding its pharmaceutical portfolio with massive investments.
This Holiday Season, See the Potential Impact that Peanut Allergy Treatment...
Did you know there’s a treatment option in addition to avoidance alone?
Notebooks, check. Backpack, check. Peanut allergy treatment, check.
What if you could give your child a treatment option, in addition to practicing a strict peanut-free diet?
Study: More Than 80% of Patients Could Tolerate 2000mg of Peanuts...
Safety and efficacy increased over time with treatment.
FARE Launches Global Research Competition to Develop a Safe, Compassionate Diagnostic...
$3 Million in prize money will inspire the world's leading food allergy researchers to put an end to the oral food challenge.
Aimmune Presents New Clinical Data From Patients Treated With PALFORZIA® for...
Majority of patients experienced low rates of adverse events which declined in frequency and severity with continued treatment.
Nestlé to Acquire Aimmune Therapeutics
Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
